Introduction: EVE-induced HG can be explained by a decrease in insulin release or increase in peripheral insulin resistance. It has been documented in 12-13% of NET pts included in phase III clinical trials based on investigators reports.
Aim(s): To evaluate the clinical relevance and predictive value of EVE-induced HG among pts with advanced NETs.
Materials and methods: Retrospective study of pts with advanced G1-G2 gastroenteropancreatic and lung NETs treated with EVE at 7 Spanish University hospitals. The highest blood sugar level during EVE therapy was considered. A multivariate Cox model controlling for previous diabetes (DM), primary tumour site, grade and prior treatments was used to compare progression-free survival (PFS) across HG CTC grades (gr).
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: MD Ana Custodio
, Jiménez-Fonseca P
, Alonso-Orduña V
, López López C
, Alonso T
, Guillermo C
, Carmona-Bayonas A
, Álvarez-Escolá C
, Solís M P
, Capdevila J
, Grande E
, Barriuso J
, Feliu J
, Aller J
To read results and conclusion, please login ...
Further abstracts you may be interested in